Preclinical findings indicate that anti-PD-1/PD-L1 therapy can induce a shift in macrophage polarization from the M2 to the M1 phenotype, thereby converting the immunosuppressive microenvironment into a pro-inflammatory state, ultimately leading to prolonged survival in mice afflicted with GBM (23). Here, PDCD1 is linked to glioblastoma.